Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment.

Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment. Abstract Text:

Recent advances in corneal graft technology, including donor tissue retrieval, storage and surgical techniques, have greatly improved the clinical outcome of corneal grafts. Despite these advances, immune mediated corneal graft rejection remains the single most important cause of corneal graft failure. Several host factors have been identified as conferring a "high risk" status to the host. These include: more than two quadrant vascularisation, with associated lymphatics, which augment the afferent and efferent arc of the immune response; herpes simplex keratitis; uveitis; silicone oil keratopathy; previous failed (rejected) grafts; "hot eyes"; young recipient age; and multiple surgical procedures at the time of grafting. Large grafts, by virtue of being closer to the host limbus, with its complement of vessels and antigen-presenting Langerhans cells, also are more susceptible to rejection. The diagnosis of graft rejection is entirely clinical and in its early stages the clinical signs could be subtle. Graft rejection is largely mediated by the major histocompatibility antigens, minor antigens and perhaps blood group ABO antigens and some cornea-specific antigens. Just as rejection is mediated by active immune mediated events, the lack of rejection (tolerance) is also sustained by active immune regulatory mechanisms. The anterior chamber associated immune deviation (ACAID) and probably, conjunctiva associated lymphoid tissue (CALT) induced mucosal tolerance, besides others, play an important role. Although graft rejection can lead to graft failure, most rejections can be readily controlled if appropriate management is commenced at the proper time. Topical steroids are the mainstay of graft rejection management. In the high-risk situations however, systemic steroids, and other immunosuppressive drugs such as cyclosporin and tacrolimus (FK506) are of proven benefit, both for treatment and prevention of rejection.

Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment. Journal Published:

PUBLICATION TYPE: Review

Journal: Indian journal of ophthalmology

VOLUME: 47

Page Numbers: 3-9

Journal Abbreviation: Indian J Ophthalmol

ISSN: 0301-4738

DAY: 3

MONTH: Mar

YEAR: 1999

Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment. Information

Number of References: 57

LANGUAGE: eng

NlmUniqueID: 405376

Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment. Keywords Mesh Terms:

KEYWORDS: Risk Factors

MESH TERMS: therapy

Chemical & Substance for Abstract: Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment.

AFFILIATION: Department of Ophthalmology (HSD), Queen's Medical Centre, University Hospital, Nottingham, UK.

Country: India

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Indian J Ophthalmol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment Related Publications

• A review of glaucoma treatment in Scotland 1994-2004.
• Allo-limbal transplantation in patients with limbal stem cell deficiency.
• Amniotic membrane transplantation.
• Autologous limbal transplantation in patients with unilateral corneal stem cell deficiency.
• Cannabinoids and glaucoma.
• Corneal allograft rejection: risk factors, diagnosis, prevention, and treatment.
• Increasing the size of a small peripheral iridotomy widens the anterior chamber angle: an ultrasound biomicroscopy study.
• Laser peripheral iridoplasty for angle-closure.
• Lower corneal hysteresis in glaucoma patients with acquired pit of the optic nerve (APON).
• Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension.
• The quality of reporting of diagnostic accuracy studies in glaucoma using scanning laser polarimetry.